While trade names often attract the attention of marketers and patients, the greater benefit for medical practice lies in the logic of International Nonproprietary Names (INNs). These are not only unified identifiers, but also convey pharmacological information \u2013 a kind of \u2018linguistic coding\u2019.
\nClassification by name stems
\nMany INN endings have a signalling function and make orientation easier:
\n\u2011olol = beta blockers (metoprolol, bisoprolol)
\n\u2011pril = ACE inhibitors (enalapril, lisinopril)
\n\u2011sartan = AT1 antagonists (valsartan, losartan)
\n\u2011mab = monoclonal antibodies (adalimumab, trastuzumab)
\n\u2011tinib = tyrosine kinase inhibitors (imatinib, osimertinib)
\nParticularly in the case of oncological agents, where new substances are approved every year, this systematic structure is an important tool for classifying the mechanism of action at least roughly. Of course, the full therapeutic context must be further differentiated.
\nDifferentiation and pitfalls
\nHowever, the nomenclature is not always intuitive. Suffixes such as \u2011ximab (chimeric mAbs) or \u2011zumab (humanised mAbs) represent subtle structural differences that are clinically relevant, for example in terms of immunogenicity. The situation regarding \u2011tinibs is similar: not every tyrosine kinase inhibitor attacks the same target, even if the name suggests that the substances are closely related.
\nIn addition, similar-sounding names carry risks: hydralazine versus hydroxyzine, celecoxib versus Celexa\u00ae (citalopram, USA). International authorities such as the EMA and FDA therefore strictly check for possible confusion, but in clinical reality, \u2018look-alike, sound-alike drugs\u2019 remain an issue \u2013 with documented medication errors.
\nBenefits in everyday medical practice
\nEspecially in hospital settings, where trade names can vary depending on the country or even the hospital form, orientation via INN endings is often the more reliable strategy. A ward doctor immediately recognises that a drug ending in \u2011pril or \u2011sartan belongs to antihypertensive therapy \u2013 even if he has never encountered the brand name before.
\nLinguistic balance
\nA recurring topic in WHO expert committees is the tension between precision and practicality. Tongue twisters such as \u2018obinutuzumab\u2019 are scientifically correct, but not very user-friendly in everyday life. This is where the balancing act comes in: as much information as necessary, as concise as possible.
\nWhen names make a big impression: Tall Man lettering
\nA somewhat unconventional but very effective trick in drug nomenclature is Tall Man lettering. This involves deliberately capitalising certain letters in an active ingredient name \u2013 for example, predniSONE and predniSOLONE. The emphasis is intended to make similar-looking names more distinguishable and thus prevent medication errors.
\nAnd why is it called \u2018Tall Man\u2019? Quite literally: the large letters \u2018stand out\u2019 like tall people in a crowd \u2013 they are not easily overlooked. This is intended to help doctors and pharmacists recognise more quickly in everyday life that these are two different substances.
\nConclusion
\nFor doctors, drug names are more than just labels \u2013 they are tools for orientation. Name stems enable quick classification, endings often reveal the mechanism of action, and differences in syllables can have clinical relevance. Those who are familiar with the system have an advantage: in recognising new substances, avoiding confusion and quickly transferring guidelines into prescription practice. And if necessary, CAPITALISATION helps\u2026<\/p>\n","protected":false},"excerpt":{"rendered":"
While trade names often attract the attention of marketers and patients, the greater benefit for medical practice lies in the logic of International Nonproprietary Names (INNs). These are not only unified identifiers, but also convey pharmacological information \u2013 a kind of \u2018linguistic coding\u2019. Classification by name stems Many INN endings have a signalling function and [\u2026]<\/p>\n","protected":false},"author":4,"featured_media":1891,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-1893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en"],"yoast_head":"\n